Hutchison China MediTech Limited
HCM
|
$18.405
0.85%
0.84%
58K
|
Health Technology
(0.0% 1d) (8.6% 1m) (25.3% 1y) (0.0% 2d) (7.7% 3d) (10.6% 7d) (-18.24% volume)
Earnings Calendar:
Market Cap: $ 3,207,094,330
http://www.chi-med.com
Sec Filling | Patents | 853 employees
Hutchison China MediTech Ltd. is a holding company, which engages in the research and development, manufactures, and sells pharmaceuticals and health oriented consumer products. It operates through the Innovation Platform and Commercial Platform segments. The Innovation Platform segment relates to research and development of innovative therapeutics in oncology and autoimmune diseases. The Commercial Platform segment relates to prescription drugs which develops, manufacture, markets, and sale of prescription pharmaceuticals; and consumer health which comprised of development, manufacture, distribution, and marketing of over-the-counter pharmaceuticals, and consumer health products. The company was founded in June 2000 and is headquartered in Hong Kong.
china autoimmunity
add to watch list Paper trade email alert is off
Press-releases
HUTCHMED Highlights Data to be Presented at AACR Congress 2024
Published: 2024-04-05 (Crawled : 09:00) - globenewswire.com
HCM | $18.405 0.85% 0.84% 58K
|
Health Technology
|
| O: -0.66%
H: 0.0%
C: -1.86%
HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status
Published: 2024-04-02 (Crawled : 05:00) - globenewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: -2.79%
H: 1.32%
C: 1.18%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -1.14%
H: 0.02%
C: -1.06%
HCM | $18.405 0.85% 0.84% 58K
|
Health Technology
|
| O: 0.21%
H: 1.49%
C: -0.06%
treatment advanced china
HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naïve or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC
Published: 2024-03-28 (Crawled : 00:00) - globenewswire.com
HCM | $18.405 0.85% 0.84% 58K
|
Health Technology
|
| O: 0.47%
H: 0.71%
C: -0.77%
advanced china
HUTCHMED Initiates Registration Stage of the ESLIM-02 Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China
Published: 2024-03-22 (Crawled : 00:00) - globenewswire.com
HCM | $18.405 0.85% 0.84% 58K
|
Health Technology
|
| O: -4.4%
H: 0.97%
C: -0.73%
eslim-02 antibody anemia trial china
HUTCHMED Highlights Presentation of Phase III Data on Fruquintinib in Second-Line Gastric Cancer at ASCO Plenary Series Session
Published: 2024-02-07 (Crawled : 00:00) - globenewswire.com
HCM | $18.405 0.85% 0.84% 58K
|
Health Technology
|
| O: 0.0%
H: 1.85%
C: 1.41%
presentation asco cancer series
HUTCHMED Announces that Inmagene Exercises Option to License Two Drug Candidates as Part of Strategic Partnership
Published: 2024-02-02 (Crawled : 09:00) - globenewswire.com
HCM | $18.405 0.85% 0.84% 58K
|
Health Technology
|
| O: -3.02%
H: 0.0%
C: -1.44%
partnership license
HUTCHMED Receives ELUNATE® (fruquintinib) Marketing Approval in Hong Kong for Treatment of Metastatic Colorectal Cancer
Published: 2024-01-30 (Crawled : 05:00) - globenewswire.com
HCM | $18.405 0.85% 0.84% 58K
|
Health Technology
|
| O: -0.85%
H: 0.62%
C: -1.17%
elunate approval cancer treatment
HUTCHMED Announces NDA Acceptance in China for Sovleplenib for the Treatment of Primary Immune Thrombocytopenia with Priority Review Status
Published: 2024-01-11 (Crawled : 00:00) - globenewswire.com
HCM | $18.405 0.85% 0.84% 58K
|
Health Technology
|
| O: 3.42%
H: 0.9%
C: -0.18%
review treatment china
HUTCHMED Announces Continued Inclusion of ELUNATE® (fruquintinib) and SULANDA® (surufatinib) in the National Reimbursement Drug List in China at Current Terms
Published: 2023-12-13 (Crawled : 05:00) - globenewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 0.32%
H: 0.0%
C: 0.0%
HCM | $18.405 0.85% 0.84% 58K
|
Health Technology
|
| O: -2.54%
H: 3.89%
C: 3.41%
elunate drug china
HUTCHMED Announces that it has Completed Enrollment of a Phase II/III Trial of Fruquintinib in Combination with Sintilimab for Advanced Renal Cell Carcinoma in China
Published: 2023-12-13 (Crawled : 00:00) - globenewswire.com
HCM | $18.405 0.85% 0.84% 58K
|
Health Technology
|
| O: -2.54%
H: 3.89%
C: 3.41%
renal cell trial advanced china
Last 15 days Sec forms
| File Id | Form | Published Date | Transaction Date | Direction | Code | Amount Transacted | Owned Amount |
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Last 48 Hours Insiders Buying
RKT P 347 | $12.55 -0.63% 0.48% 1.7M
|
Finance
|
22:30
NWFL | News | $24.6 2.03% 1.99% 9.9K
|
Finance
|
22:00
TGEN P 10000 | $0.685 39.71% 6.6K
|
Utilities
|
20:01
MNSB P 310 | $15.88 -2.93% -3.02% 46K
|
Finance
|
15:30
RMCF | $3.54 0.28% 7.1K
|
Consumer Non-Durables
|
20:10